Advertisement
News
Advertisement

Fujifilm Announces New Platform in Digital Mammography Portfolio – Amulet Innovality* at RSNA 2013

Sun, 12/01/2013 - 11:00am
Business Wire

Today at the 99th annual meeting of the Radiological Society of North America (RSNA), FUJIFILM Corporation, Tokyo, Japan, introduced its latest and most innovative digital mammography system, the Amulet Innovality* in Chicago, IL. The Amulet Innovality is not commercially available in the United States. When it becomes available in the US it will be named the Aspire Cristalle**.

“Our newest full field digital mammography system is brilliantly designed to offer both 2D and advanced applications for the most confident diagnoses,” said David Hotchkiss, director of marketing, Women’s Health, CR, FUJIFILM Medical Systems U.S.A., Inc. “Now the radiologist can see breast tissue detail in a way that was never seen before in sharper, clearer images and can make confident diagnostic interpretations.” Among the many new features of the Amulet Innovality**** is the ability of this system to utilize advanced applications which includes the ability to do breast tomosynthesis studies***. Since launching CR products, Fujifilm has demonstrated a commitment to introducing innovative, meaningful technology that will enable our customers to diagnose breast cancer earlier and save more lives. Fujifilm will continue to provide those breakthrough innovations as it increasingly invests in new approaches to breast imaging. The Amulet Innovality also has been designed to enhance patient comfort and the patient experience during annual exams.

To register for a product demonstration at RSNA, please visit http://rsna.fujimed.com. For every product demonstration registered online, Fujifilm will donate $25 to the National Breast Cancer Foundation. For more information about Fujifilm’s Aspire Breast Imaging Solutions, please visit: http://digital-mammography.fujimed.com.

*The Amulet Innovality is not commercially available in the United States
** The ASPIRE Cristalle will be made commercially available in the United States upon receipt of FDA clearance. Caution: Investigational Device . Limited by U.S. Federal Law to Investigational Use.
***Tomosynthesis functionality for ASPIRE Cristalle is not commercially available in the United States.
****The Amulet Innovality will be known as Aspire Cristalle once available in the United States

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading